Stay updated on Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial
Sign up to get notified when there's something new on the Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial page.

Latest updates to the Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check30 days agoNo Change Detected
- Check38 days agoChange DetectedThe page now includes a notice about heavy traffic affecting NLM-NCBI services and updates to several future dates, while some previous dates have been removed.SummaryDifference2%
- Check45 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check59 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check66 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
- Check81 days agoChange DetectedNew results have been posted, including the Overall Response Rate and Progression Free Survival metrics, with significant updates on submission and posting dates, while previous results and updates from May 2023 have been removed.SummaryDifference2%
Stay in the know with updates to Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial page.